Progress and prospects of anti-IL-4/IL-13 monoclonal antibody treatment in chronic rhinosinusitis with nasal polyps.
10.13201/j.issn.2096-7993.2025.12.017
- Author:
Ziqi MIAO
1
;
Yuqin DENG
1
Author Information
1. Department of Otolaryngology Head and Neck Surgery，Renmin Hospital of Wuhan University，Wuhan，430060，China.
- Publication Type:English Abstract
- Keywords:
IL-4/IL-13;
biologics;
chronic rhinosinusitis with nasal polyps;
type Ⅱ inflammation
- MeSH:
Humans;
Nasal Polyps/therapy*;
Sinusitis/therapy*;
Chronic Disease;
Interleukin-13/antagonists & inhibitors*;
Antibodies, Monoclonal/therapeutic use*;
Interleukin-4/antagonists & inhibitors*;
Rhinitis/drug therapy*;
Rhinosinusitis
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2025;39(12):1197-1202
- CountryChina
- Language:Chinese
-
Abstract:
Chronic rhinosinusitis（CRS） is a chronic inflammation of the nasal cavity and sinus mucosa, which is mainly characterized by nasal obstruction, runny nose, headache and hyposmia. Due to complex mechanisms, CRS can be divided into different clinical phenotypes and inflammatory endotypes. Approximately 80% of chronic rhinosinusitis with nasal polyps（CRSwNP） patients present with type Ⅱ inflammation. IL-4 and IL-13 are the key factors in the process of type Ⅱ inflammation, and drugs targeting IL-4/IL-13 provide new options for the treatment of CRSwNP. Therefore, this article mainly reviews the application of anti-IL-4 /IL-13 monoclonal antibody in CRSwNP.
